BCCA Protocol Summary for Palliative Therapy for Aggressive Fibromatosis Using Weekly or Alternate Week Methotrexate and vinBLASTine Intravenously

**Protocol Code**  
SAMV

**Tumour Group**  
SARCOMA

**Contact Physician**  
Dr. Meg Knowling

**ELIGIBILITY:**
- Fibromatosis not responding to hormonal therapy

**EXCLUSIONS:**
- Calculated creatinine clearance less than 30 mL/min
- Large third space fluid accumulations (significant ascites, large pleural effusion or other large lobulated fluid accumulations)

**TESTS:**
- Baseline: CBC & Diff, platelet, bili, alk phos, AST, LDH, GGT, albumin, creatinine, lytes and chest X-ray and best imaging site(s) of disease
- Before each treatment: CBC & Diff, platelet
- If clinically indicated: Imaging should be repeated every 3 to 4 months

**PREMEDICATIONS:**
- Antiemetic protocol for low emetogenic chemotherapy protocols (see SCNAUSEA)

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>methotrexate</td>
<td>30 mg/m²</td>
<td>IV push</td>
</tr>
<tr>
<td>vinBLASTine</td>
<td>6 mg/m²</td>
<td>IV in 50 mL NS over 15 minutes</td>
</tr>
</tbody>
</table>

Repeat every 7 or 14 days (28 days = 1 cycle) x 12 cycles- 1 year  
Discontinue if progression on imaging at 3 or 4 months.

**DOSE MODIFICATIONS:**

1. **Hematological**

<table>
<thead>
<tr>
<th>ANC (x10⁹/L)</th>
<th>Platelets (x10⁹/L)</th>
<th>Dose (all drugs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than 0.9 and greater than 99</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>0.5 to 0.9 or 50 to 99</td>
<td>50%</td>
<td></td>
</tr>
<tr>
<td>less than 0.5 or less than 50</td>
<td>delay*</td>
<td></td>
</tr>
</tbody>
</table>

*Baseline vinBLASTine dose reduced by 25% if chemotherapy delayed 2 or more weeks.
2. **Mucositis**: Methotrexate: reduced by 50% or 100% for NCI common Toxicity Criteria grade 1 or 2, respectively

3. **Renal dysfunction**: Methotrexate: temporarily withhold for elevations of serum creatinine (greater than 3X upper limit of normal)

4. **Hepatic dysfunction**: Methotrexate: temporarily withhold for elevations of bilirubin (greater than 1.5 X upper limit of normal) or AST or ALT (greater than 5X upper limit of normal.)

5. **Significant third space fluids** (ascites, pleural effusions): Reconsider treatment

6. **Neuropathy**: vinBLASTine was temporarily withheld for grade 2 neuropathy or greater.

**PRECAUTIONS:**

1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively. Refer to BCCA Febrile Neutropenia Guidelines.

2. **Extravasation**: vinBLASTine may cause pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines

Call Dr. Meg Knowling or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 01 April 2007

Date revised: 1 Feb 2015 (vinBLASTine administration revised)

**References:**
